Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease

Kelvin K. W. Cheng, Diane M. A. Swallow, Katherine A. Grosset, Donald G. Grosset

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and aims: Vascular disease is a common comorbidity in Parkinson’s disease patients. Statins are potentially neuroprotective for Parkinson’s disease through non-vascular mechanisms. We investigated prevailing statin use in a Parkinson’s disease cohort. 

Methods and results: Data on diagnostic indication for statins, anti-Parkinson therapy, vascular risk factors, and statin prescription, were obtained from electronic medical record review for consecutive Parkinson’s disease patients. The ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network system was used to calculate future cardiovascular risk and identify those warranting statin use. Of 441 patients included, 59.9% were male, with a mean age of 68.9 years (standard deviation 10.3). One hundred and seventy-four (39.5%) patients had at least one diagnostic indication for statin use, of whom 136 (78.2%) were prescribed a statin. In the 267 (60.5%) cases without a diagnostic indication, 54 (20.2%) were excluded owing to age limitations defined in ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network. Of the remaining 213, 62 (29.1%) had an ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network score in the recommended range for statin therapy, of whom 15 (24.1%) were prescribed statins. 

Conclusion: There is suboptimal implementation of statin therapy in Parkinson’s disease patients. Given the possible neuroprotective effects of statins in Parkinson’s disease in addition to reducing cardiovascular risk, reasons for suboptimal implementation warrant further investigation.

Original languageEnglish
Pages (from-to)104-109
Number of pages6
JournalScottish Medical Journal
Volume62
Issue number3
Early online date24 Aug 2017
DOIs
Publication statusPublished - 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Blood Vessels
Parkinson Disease
vascular factor
Electronic Health Records
Vascular Diseases
Comorbidity
Therapeutics
Guidelines

Keywords

  • Journal Article
  • Parkinson’s disease
  • statin
  • cardiovascular disease
  • cardiovascular risk
  • neuroprotection

Cite this

Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease. / Cheng, Kelvin K. W.; Swallow, Diane M. A.; Grosset, Katherine A.; Grosset, Donald G.

In: Scottish Medical Journal, Vol. 62, No. 3, 2017, p. 104-109.

Research output: Contribution to journalArticle

Cheng, Kelvin K. W. ; Swallow, Diane M. A. ; Grosset, Katherine A. ; Grosset, Donald G. / Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease. In: Scottish Medical Journal. 2017 ; Vol. 62, No. 3. pp. 104-109.
@article{eaadbb2242094e11b13d168a624854d0,
title = "Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease",
abstract = "Background and aims: Vascular disease is a common comorbidity in Parkinson’s disease patients. Statins are potentially neuroprotective for Parkinson’s disease through non-vascular mechanisms. We investigated prevailing statin use in a Parkinson’s disease cohort. Methods and results: Data on diagnostic indication for statins, anti-Parkinson therapy, vascular risk factors, and statin prescription, were obtained from electronic medical record review for consecutive Parkinson’s disease patients. The ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network system was used to calculate future cardiovascular risk and identify those warranting statin use. Of 441 patients included, 59.9{\%} were male, with a mean age of 68.9 years (standard deviation 10.3). One hundred and seventy-four (39.5{\%}) patients had at least one diagnostic indication for statin use, of whom 136 (78.2{\%}) were prescribed a statin. In the 267 (60.5{\%}) cases without a diagnostic indication, 54 (20.2{\%}) were excluded owing to age limitations defined in ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network. Of the remaining 213, 62 (29.1{\%}) had an ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network score in the recommended range for statin therapy, of whom 15 (24.1{\%}) were prescribed statins. Conclusion: There is suboptimal implementation of statin therapy in Parkinson’s disease patients. Given the possible neuroprotective effects of statins in Parkinson’s disease in addition to reducing cardiovascular risk, reasons for suboptimal implementation warrant further investigation.",
keywords = "Journal Article, Parkinson’s disease, statin, cardiovascular disease, cardiovascular risk, neuroprotection",
author = "Cheng, {Kelvin K. W.} and Swallow, {Diane M. A.} and Grosset, {Katherine A.} and Grosset, {Donald G.}",
note = "Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: DGG has received honoraria from UCB Pharma, GE Healthcare and consultancy fees from Acorda Inc.",
year = "2017",
doi = "10.1177/0036933017727432",
language = "English",
volume = "62",
pages = "104--109",
journal = "Scottish Medical Journal",
issn = "0036-9330",
publisher = "SAGE PUBLICATIONS LTD",
number = "3",

}

TY - JOUR

T1 - Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease

AU - Cheng, Kelvin K. W.

AU - Swallow, Diane M. A.

AU - Grosset, Katherine A.

AU - Grosset, Donald G.

N1 - Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: DGG has received honoraria from UCB Pharma, GE Healthcare and consultancy fees from Acorda Inc.

PY - 2017

Y1 - 2017

N2 - Background and aims: Vascular disease is a common comorbidity in Parkinson’s disease patients. Statins are potentially neuroprotective for Parkinson’s disease through non-vascular mechanisms. We investigated prevailing statin use in a Parkinson’s disease cohort. Methods and results: Data on diagnostic indication for statins, anti-Parkinson therapy, vascular risk factors, and statin prescription, were obtained from electronic medical record review for consecutive Parkinson’s disease patients. The ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network system was used to calculate future cardiovascular risk and identify those warranting statin use. Of 441 patients included, 59.9% were male, with a mean age of 68.9 years (standard deviation 10.3). One hundred and seventy-four (39.5%) patients had at least one diagnostic indication for statin use, of whom 136 (78.2%) were prescribed a statin. In the 267 (60.5%) cases without a diagnostic indication, 54 (20.2%) were excluded owing to age limitations defined in ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network. Of the remaining 213, 62 (29.1%) had an ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network score in the recommended range for statin therapy, of whom 15 (24.1%) were prescribed statins. Conclusion: There is suboptimal implementation of statin therapy in Parkinson’s disease patients. Given the possible neuroprotective effects of statins in Parkinson’s disease in addition to reducing cardiovascular risk, reasons for suboptimal implementation warrant further investigation.

AB - Background and aims: Vascular disease is a common comorbidity in Parkinson’s disease patients. Statins are potentially neuroprotective for Parkinson’s disease through non-vascular mechanisms. We investigated prevailing statin use in a Parkinson’s disease cohort. Methods and results: Data on diagnostic indication for statins, anti-Parkinson therapy, vascular risk factors, and statin prescription, were obtained from electronic medical record review for consecutive Parkinson’s disease patients. The ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network system was used to calculate future cardiovascular risk and identify those warranting statin use. Of 441 patients included, 59.9% were male, with a mean age of 68.9 years (standard deviation 10.3). One hundred and seventy-four (39.5%) patients had at least one diagnostic indication for statin use, of whom 136 (78.2%) were prescribed a statin. In the 267 (60.5%) cases without a diagnostic indication, 54 (20.2%) were excluded owing to age limitations defined in ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network. Of the remaining 213, 62 (29.1%) had an ASsessing cardiac risk using Scottish Intercollegiate Guidelines Network score in the recommended range for statin therapy, of whom 15 (24.1%) were prescribed statins. Conclusion: There is suboptimal implementation of statin therapy in Parkinson’s disease patients. Given the possible neuroprotective effects of statins in Parkinson’s disease in addition to reducing cardiovascular risk, reasons for suboptimal implementation warrant further investigation.

KW - Journal Article

KW - Parkinson’s disease

KW - statin

KW - cardiovascular disease

KW - cardiovascular risk

KW - neuroprotection

U2 - 10.1177/0036933017727432

DO - 10.1177/0036933017727432

M3 - Article

VL - 62

SP - 104

EP - 109

JO - Scottish Medical Journal

JF - Scottish Medical Journal

SN - 0036-9330

IS - 3

ER -